gastric cancer
Conditions
Interventions
neoadjuvant group:neoadjuvant Docetaxel/Oxaliplatin/Xelode (DOX)
Control:Neoadjuvant Docetaxel/Oxaliplatin/Xelode (DOX) three weeks and eight weeks courses
Sponsors
the First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Volunteers with informed consent; 2. To be aged 18 to 75 years old; 3. ECOG score less than 0-1; 4. fertile woman accepted for contraception during the study; 5. gastric cancer confirmed by histology; 6. preoperative staging is T4N+M0 with CT and ultrasonic endoscope, and possibly resectable; 7. without distant metastasis, without para-aortic lymph node metastasis; 8. maximum diameter more than at least 1cm measured by spiral CT, or more than at least 2cm measured by normal CT/MRI; 9. without neoadjuvant chemotherapy before this study; 10. hepatorenal bone marrow functions suitable for chemotherapy; 11. suitalbe for abdominal surgery.
Exclusion criteria
Exclusion criteria: 1. To be aged younger than 18 or older than 75 years old; 2. ECOG score more than 1; 3. suspicious distant metastasis; 4. unsuitable for chemotherapy; 5. severe gastrointestinal bleeding; 6. tumor with deep ulcer; 7. with severe cardiovascular disease, hepatorenal disfunction, neuropsychiatric disease or acute infection; 8. poorly controlled diabetes and hypertension; 9. pregnant orlactating women; 10. unwilling for contraception; 11. malabsorption or upper gastrointestinal tract obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radical resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence-free survival;Chemotherapy reaction; | — |
Countries
China
Contacts
Public ContactZekuan Xu
the First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed